We leverage the power of the innate and adaptive immune systems with the goal of long-term tumor remissions for patients We leverage the power of the innate and adaptive immune systems with the goal of long-term tumor remissions for patients

Our Approach

Bolt is pioneering a new category of targeted immunotherapies that leverage the precision of antibody targeting with the activation of the innate and adaptive immune systems in the tumor microenvironment.

Patients

BDC-1001 is a HER2 Boltbody™ ISAC that is currently in clinical development for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors.

Our Team

Bolt is a world-class, inclusive community of fearless innovators committed to delivering transformative treatments to cancer patients with unmet medical needs.

Our Approach

Bolt is pioneering a new category of targeted immunotherapies that leverage the precision of antibody targeting with the activation of the innate and adaptive immune systems in the tumor microenvironment.

Patients

BDC-1001 is a HER2 Boltbody™ ISAC that is currently in clinical development for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors.

Our Team

Bolt is a world-class, inclusive community of fearless innovators committed to delivering transformative treatments to cancer patients with unmet medical needs.

Pipeline

Utilizing our Boltbody™ ISAC approach and myeloid biology expertise, we have a built a robust pipeline of immune-stimulating, myeloid-engaging therapeutics.

PlatformTargetIndicationDISCOVERYPRE-CLINICALPHASE I/II
Boltbody ISAC HER2
  • HER2+ Breast Cancer
  • HER2 Low Breast Cancer
  • HER2+ Gastric Cancer
  • Other HER2+ Cancers

PHASE I/II

BDC-1001
Boltbody ISAC CEA
  • Non-Small Cell Lung Cancer
  • Colorectal Cancer
  • Pancreatic Cancer
  • Breast Cancer

PRE-CLINICAL

Boltbody ISAC PD-L1
  • Checkpoint Inhibitor Refractory Tumors

PRE-CLINICAL

Myeloid ModulatorTAM1
  • KRAS mutated cancer
  • TP53 mutated cancer

PRE-CLINICAL

Highlights

Press Release

Press Release

Bolt Biotherapeutics Expands Board of Directors with Appointment of Kathleen LaPorte

Press Release

Press Release

Bolt Biotherapeutics Presents Ongoing Clinical Trial Poster at San Antonio Breast Cancer Symposium 2020 Virtual Meeting

Press Release

Press Release

Data Published in Nature Cancer Highlight Preclinical Proof of Concept of Bolt Biotherapeutics’ Boltbody™ ISAC Platform

Podcast

Podcast

Dr. Randy Schatzman On Dodging Disruption: The New Fundraising Norm

Business of Biotech Podcast